Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

WHO Recommends Pre-Exposure Prophylaxis for Men Who Have Sex with Men

Gay and bisexual men who are at risk for HIV infection should consider using antiretroviral drugs for pre-exposure prophylaxis (PrEP), according to new guidelines from the World Health Organization (WHO), part of a set of recommendations for key populations affected by the HIV/AIDS epidemic.

alt

Read more:

New Studies Offer More Insight on HIV Sexual Transmission and Prevention

A new estimate puts the likelihood of HIV transmission via receptive anal sex at 138 per 10,000 acts, but looking at probabilities over a longer period provides a better understanding of risk than per-act probabilities, according to a pair of studies in the May 6 advance online edition of AIDS. Mathematical models showed that combining prevention methods -- especially those that include antiretroviral treatment-as-prevention or PrEP -- can greatly reduce the risk of transmission.

alt

Read more:

New CDC Guidelines: People at Risk for HIV Should Consider Truvada PrEP

Healthcare providers should advise people at "substantial risk" for HIV infection about pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine, or Truvada, according to new guidelines issued by the U.S. Centers for Disease Control and Prevention (CDC). This includes HIV negative people in an ongoing sexual relationship with HIV positive partners, gay or bisexual men who have had sex without condoms during the past 6 months, heterosexual men and women who have sex without condoms with at-risk partners, and injection drug users.

alt

Read more:

San Francisco HIV Forum Asks: Is Undetectable the New Negative?

More than 100 participants packed the Eureka Valley Recreation Center in San Francisco on May 20 for the latest Real Talk discussion of new HIV prevention strategies including pre-exposure prophylaxis (PrEP) and antiretroviral treatment as prevention.

alt

Read more:

New Recommendations for Earlier HIV Screening and PrEP for Women

The American College of Obstetricians and Gynecologists last week issued 2 new recommendations on screening and prevention of HIV in women. The first matches the CDC's recommendation that HIV screening should start at age 13 and should be offered at least annually to at-risk women. The second advises that pre-exposure prophylaxis (PrEP) -- using antiretroviral medications such as Truvada to prevent HIV infection -- may be a useful tool for women at highest risk, including those with HIV positive male partners.

alt

Read more: